Generate a tailored SOP for Dr. Jongbok Lee. Improve your application with a focused, well-structured draft.
Jongbok Lee is an immunotherapy researcher focusing on the study of specific immune cell therapies, particularly allogeneic CD3+ CD4- CD8- double-negative T cells (DNTs) in treating acute myeloid leukemia (AML). He earned his Ph.D. from the University of Toronto, where he explored the safety and effectiveness of DNTs using preclinical models and investigated their potential as an 'off-the-shelf' therapy. Following his doctoral studies, he engaged in post-doctoral research at the University Health Network, where he demonstrated the efficacy of DNTs in combination with drugs like Venetoclax and Azacytidine, along with CAR T-cell technology. Dr. Lee has played a vital role in a phase clinical trial that showcased the feasibility and safety of allogeneic DNT therapy for AML patients who relapsed after undergoing hematopoietic stem cell transplantation. His research seeks to identify the underlying mechanisms involved in DNT-mediated anti-cancer activities, aiming to develop precise therapeutic approaches that positively impact patients’ lives.
Cumming School of Medicine • Calgary, AB, Canada
Conducting research in immunotherapy, focusing on double-negative T cells and cancer treatment.
Department of Computer Science Master's program. GRE scores are expected for international students.